// App-Quantinova.ai

4000 : Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.

Researchers

Presenter

  • Lorenza Rimassa

Principal Investigators

  • Markus Peck-Radosavljevic

  • Vittorina Zagonel

  • Marc Pracht

  • Elena Rota Caremoli

  • Philippe Mathurin

  • William Proctor Harris

  • Luigi Bolondi

  • Maria Reig

  • Nevena Damjanov

  • Bruno Daniele

  • Camillo Porta

  • Vincenzo Mazzaferro

  • Giovanni Abbadessa

  • Brian E. Schwartz

  • Maria Lamar

  • Terri Robin Goldberg

  • Armando Santoro

  • Jordi Bruix

Medical Centers

  • Humanitas Cancer Center, Humanitas Clinical and Research Hospital, Rozzano, Italy

  • Service d'Oncologie Medicale, CHRU Saint Eloi, Montpelier, France

  • Department of Gastroenterology/Hepatology, Medizinische Universitaet Wien, Allgemeines Krankenhaus der Stadt Wien, Wien and Department of Gastroenterology/Hepatology, Klinikum Klagenfurt am Worthersee, Klagenfurt, Austria

  • Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology, Veneto Institute of Oncology IOV IRCCS, Padua, Italy

  • Service d'Oncologie Medicale, Central Eugene Marquis, Rennes, France

  • Papa Giovanni XXIII Hospital, Bergamo, Italy

  • Hopital Claude Huriez, Lille, France

  • University of Washington School of Medicine, Seattle, WA

  • Department of Medical and Surgical Sciences, University of Bologna and Center for Applied Biomedical Research (CRBA), S.Orsola-Malpighi Hospital, Bologna, Italy

  • Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain

  • Abramson Cancer Center, Philadelphia, PA

  • G.Rummo Hospital, Benevento, Italy

  • IRCCS San Matteo University Hospital Foundation, Padua, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • ArQule, Inc., Burlington, MA

  • Daiichi Sankyo Co., Ltd., Edison, NJ

  • Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain

Locations

  • Italy

  • Austria

  • Spain

  • United States

  • France

Companies

  • ArQule, Inc.

  • Daiichi Sankyo Compa

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Alpha-fetoprotein

Drug/Treatment

  • Tivantinib

  • Sorafenib

  • ARQ 197

Outcome

  • Negative

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT01755767

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved